U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Inspections, Compliance, Enforcement, and Criminal Investigations
  3. Criminal Investigations
  4. Press Releases
  5. Lexington Doctor Sentenced for Engaging in International Money Laundering Scheme and Importing Illegal and Misbranded Drugs
  1. Press Releases

Lexington Doctor Sentenced for Engaging in International Money Laundering Scheme and Importing Illegal and Misbranded Drugs

OCI badge

Department of Justice
U.S. Attorney's Office
District of Massachusetts 

FOR IMMEDIATE RELEASE
Tuesday, December 17, 2024

Defendant falsified documents to obtain drugs from Hong Kong that are not FDA-approved


BOSTON – A Lexington, Mass. doctor was sentenced yesterday in federal court in Boston for an international money laundering scheme involving importing illegal, misbranded drugs.

Rahim Shafa, 66, was sentenced by U.S. District Court Judge Margaret R. Guzman to three years in prison, to be followed by three years of supervised release. Shafa was also ordered to pay $115,765 in restitution and a fine of $150,000. In February 2024, Shafa was convicted after a 14-day jury trial of international money laundering, illegally importing merchandise contrary to law and receiving and delivering misbranded drugs. The defendant was indicted by a federal grand jury in August 2020 and subsequently charged in a superseding indictment in June 2021.

Shafa was a psychiatrist who owned and operated Novel Psychopharmacology (Novel). From approximately January 2008 through January 2018, Shafa engaged in an international money laundering scheme to purchase naltrexone pellet implants as well as disulfiram pellet implants and injections from Hong Kong. Naltrexone and disulfiram are approved by the U.S. Food and Drug Administration (FDA) in certain forms for the treatment of alcohol dependence and alcohol and opioid dependence, respectively. However, the implantable pellet form of the drug that Shafa purchased are not approved by the FDA. Shafa falsified shipping documents to conceal that the packages containing the drugs were shipped from Hong Kong to Shafa in Massachusetts. For example, packages containing naltrexone pellet implants were falsely declared as ‘plastic beads in plastic tubes’ in shipping documents. Shafa sold these drugs to patients of Novel and implanted them into patients, without fully understanding the risks of the drugs. Patients testified at trial regarding infections and complications they experienced from the pellet implantation procedure.

United States Attorney Joshua S. Levy, Fernando P. McMillan, Special Agent in Charge of the New York Field Office of the U.S. Food and Drug Administration, Office of Criminal Investigations and Special Agent in Charge Roberto Coviello of the U.S. Department of Health and Human Services, Office of Inspector General (HHS-OIG) made the announcement. Valuable assistance was provided by the Massachusetts State Police, the Milford Police Department and the Lexington Police Department. Assistant U.S. Attorneys John T. Mulcahy, Howard Locker and Kaitlin J. Brown of the Criminal Division prosecuted the case.
 

Back to Top